Report of the Committee on Pharmaceuticals
Chair: Liz Wagstrom, DC
Vice Chair: Timothy Goldsmith, MN

James Averill, MI; Tom Burkgren, IA; Stephen Crawford, NH; Barbara Determan, IA; William Fales, MO; Kristi Henderson, IL; Rick Hill, IA; Christine Hoang, IL; Donald Hoenig, ME; Jennifer Koeman, IA; David Marshall, NC; Shelley Mehlenbacher, VT; M. Gatz Riddell, Jr., AL; Craig Shultz, PA; Brad Williams, TX; Ellen Mary Wilson, NM.

The Committee met on October 27 at the Rhode Island Convention Center in Providence, Rhode Island from 8:00 AM to 12:00 PM. There were 9 members and 16 guests present. The committee charge was read to start the meeting.

Presentations & Reports

Dr. Peter Davies, University of Minnesota – European Antimicrobial Data Collection Schemes

Dr. Davies discussed antimicrobial use collection systems and the metrics by which they report use in the European Union. He discussed the variation in both numerators and denominators utilized to report antimicrobial use. He contrasted data sources in Europe from that available in the United States. His presentation is available on the Committee website.

Dr. Dave Dargatz, USDA NAHMS – USDA Antimicrobial Use Data Collection Activities

Dr. Dargatz provided an update on the surveillance activities around the collection of antimicrobial use. This is a portfolio approach including annual surveys, longitudinal surveys and more extensive multiyear surveys. Engagement with stakeholders to determine feasibility of the approaches. Budgetary constraints are preventing implementation of these activities. However, work is being done to position the Agency to collect data including: retrospective studies of existing data from previous NAHMS studies, further characterizing isolates from the previous studies, releasing new information from recent NAHMS studies and will add further antibiotic questions to future surveys, study of animal health information related to use and resistance via aggregation of date from veterinary diagnostic laboratories, and engaging with industry groups on data that they may be collecting. A working group to examine the variation and capacity of the laboratories to determine the feasibility of analyzing VDL data has been developed.

USDA is engaging on a global basis through WHO global initiative, the OIE, and the Global Health Security Agenda.

USDA engaging in outreach and education through the release of new information, development of veterinary accreditation modules, help with industry stewardship programs, and interaction with the Farm Foundation outreach meetings.

Dr. Charles Pixley, USDA FSIS – National Residue Program Update

Dr. Pixley gave an overview of the National Residue Program and provided preliminary data on residue violations. He outlined the increasing number of compounds analyzed for each sample collected, and the increased number of commodities sampled as part of the National Residue Program. The total violative residue prevalence was below 1%. The presentation, in its entirety, is available on the Committee website.

Dr. Peter Davies, University of Minnesota – Update on Livestock Associated MRSA

Dr. Davies presented results of global surveillance on research on strains of methicillin resistant Staph aureus. He made the point that referring to livestock associated and cc398 as equivalent

disregards the evidence that some MRSA strains other than cc398 are found in livestock, and that there are human adapted cc398 spa types that are not livestock associated. Globally the clinical impacts of livestock associated MRSA is extremely low, and there is no evidence of occupational illness associated with animal production or veterinary practice. The US appears to have a lower prevalence of MRSA in swine herds and veterinarians. The presentation, in its entirety, is included on the Committee website.

Dr. Harry Snelson, American Association of Swine Practitioners – Update on Changes to the VFD Rule, the Practitioner's Perspective.

Dr. Snelson gave an overview of practitioner responsibilities following implementation of FDA Guidance #213 and the revisions to the Veterinary Feed Directive Rule. He outlined the responsibilities of the practitioner under the revised VFD rule, including record retention, VCPR and other pertinent topics. The presentation, in its entirety, is included on the Committee website.

Dr. Michael Murphy, Center for Veterinary Medicine, Food and Drug Administration – FDA Update

Dr. Murphy gave an overview of the FDA's actions to address animal feed safety as part of the Food Safety Modernization Act. He also gave further updates on the progress of implementing Guidance 213 and the VFD rule revisions. He discussed the public meeting held on antibiotic use data collection. His presentation, in its entirety, is included on the Committee website.

Committee Business:

The committee discussed ways to build awareness of the committee's mission area. It was suggested that the mission be included on the agenda. A motion was made and seconded asking the Executive Committee to change the name of the committee from the Committee on Pharmaceuticals to the Committee on Pharmaceutical Issues. Motion passed.

The committee also passed a resolution on veterinary availability of ketamine.

Addendums: